×
SIGN UP FOR OUR MONTHLY NEWSLETTER

Making glaucoma medications easier and more affordable

Eyecare practitioners have several options for the drugs we prescribe to patients. First and generally most expensive, there are the branded, proprietary, patented drugs such as Xiidra, Rocklatan, and Vyzulta. Then there are generics—both branded generics and generics with equivalent active ingredients such as latanoprost, which are much less costly to insurance companies and patients. Read More

A drug for acute NAION is currently in phase III clinical trials

After glaucoma, the second-most common source of optic nerve damage is Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). We usually describe this to a patient as a “stroke in the eye,” where blood supply to the optic nerve is cut off due to conditions ranging from hypotension to carotid occlusive disease. This condition typically causes sudden and acute vision loss in one eye, without any pain. Some patients get marginal improvement with time, but usually the prognosis is poor. Read More

It’s safe, more affordable than ever, and useful for numerous indications

If there is one compelling example of the value of ultrasound technology in eye care, it’s an experience I had this past year. I was conducting a retina workshop at the Review of Optometry New Technology and Treatments Conference. To demonstrate how to obtain an ultrasound image, I asked for a volunteer with a pathology or symptom that would warrant a potential B-scan.Read More

What can doctors do to help low-income patients who need them?

It’s a harsh fact in the U.S. that people who live in poor rural or urban communities are more likely to have health problems and experience limited access to health care. Hospital closures have increased throughout the country, and the communities with the greatest shortage of doctors also tend to be the areas with the highest poverty. Patients there struggle to afford and access health care, while doctors face challenges related to reimbursement and patient communication. But there is hope. Read on to find out the best practices and tools that benefit not only low-income patients, but all patients, as well as the doctors who serve them. Read More

In 2019, we have access to two exciting new therapies

This past year brought some significant advances in eye care as far as new tests, technology, and drug approvals, and 2019 is looking just as promising. In 2018, we gained access to the first two new glaucoma drugs in decades. Now two more new drugs will soon be available to us. These include a new ocular corticosteroid that uses a revolutionary drug delivery technology, and a new drug that treats a rare and progressive eye disease that can lead to corneal scarring and vision loss. Here’s why I’m looking forward to trying these new therapies in my practice.Read More

New technology is on the horizon that can help you streamline your practice

New technologies are emerging that will transform ophthalmology and optometry. They may not be the ones that are on your radar, however. “While the eye care world has been fixated on telemedicine and online eye exams, robots are set to impact our 21st century world,” wrote Thomas A. Wong, O.D. in the Optometry Times.Read More